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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
bevacizumab (avastin) is safe and effective as adjuvant chemotherapy for adult patients with
stage IIIb or IV non-small cell lung carcinoma (NSCLC).
STUDY DESIGN: Review of three randomized controlled trials (RCT) published in 2006, 2009,
and 2011, all English language.
DATA SOURCES: Two randomized, double-blind, controlled clinical trials comparing
bevacizumab to placebo as adjunctive chemotherapy, and one RCT comparing bevacizumab as
adjunctive chemotherapy versus the use of no adjunctive chemotherapy. All articles were found
using PubMed, Medline, and OVID.
OUTCOMES MEASURED: Overall survival (OS) and progression-free survival (PFS) were
measured. OS was defined as time from randomization to death from any cause. PFS was
defined as time from randomization to first documented disease progression or death on study
treatment, whichever occurred first. Event-time distributions were estimated using the KaplanMeier method.
RESULTS: Herbst et al2 and Reck et al6 compared traditional chemotherapy plus bevacizumab
to traditional chemotherapy plus placebo, and Sandler et al3 compared traditional chemotherapy
plus bevacizumab to traditional chemotherapy alone. Herbst et al2 failed to find a significant
difference in OS or PFS between subjects using adjuvant bevacizumab and those using
traditional chemotherapy. Reck et al6 was unable to assess OS; however, the investigators
reported that PFS was significantly improved with the addition of bevacizumab to traditional
chemotherapy. Sandler et al3 established that the addition of bevacizumab to traditional
chemotherapy has statistically significant survival benefits in patients with NSCLC.
CONCLUSIONS: From the research performed and results obtained, the evidence is
inconclusive and conflicting to support the use of bevacizumab as adjuvant chemotherapy for
stage IIIb or IV NSCLC. With inconsistencies and differing results among the three RCTs,
further research would be helpful to confirm or negate the question of whether bevacizumab is
actually beneficial as adjuvant therapy. In addition to researching the efficacy and safety of
bevacizumab as adjuvant chemotherapy, it would be advantageous to study the efficacy and
safety of bevacizumab as monotherapy. Further research is warranted to obtain more conclusive
data.
KEY WORDS: Non-small cell lung cancer, Avastin, Bevacizumab, adjuvant chemotherapy
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INTRODUCTION
Malignant epithelial cells that form in the lung tissue cause non-small cell lung
carcinoma (NSCLC), with the most common types being squamous cell carcinoma, large cell
carcinoma, and adenocarcinoma. NSCLC may present as an incidental finding on chest imaging
or with symptoms due to either local invasion or compression of adjacent thoracic structures.
Common symptoms, which may be indicative, but are neither specific nor diagnostic for lung
cancer, include hemoptysis, worsening cough, chest pain, weight loss, malaise, dyspnea, and/or
hoarseness.1 As a class, NSCLCs are reasonably unresponsive to chemotherapy and radiation
therapy. Nevertheless, the addition of bevacizumab as adjunctive treatment to traditional
chemotherapy, has been investigated as an option for patients with NSCLC that is refractory to
treatment.1 This paper evaluates three randomized controlled trials (RCT) comparing the efficacy
and safety of bevacizumab (avastin) as adjuvant chemotherapy for adult patients with stage IIIb
or IV NSCLC.
NSCLC is a major cause of illness, disability, and death. Lung cancer is the leading cause
of death worldwide, with more than 85% of lung cancers being NSCLC.1,2,3 Due to vague
presenting symptoms or incidental findings on imaging, around 75% of NSCLC patients are
initially diagnosed with advanced metastatic disease.2 National cancer care expenditure for lung
cancer is an estimated $12.12 billion, with lost time and economic productivity being greatest for
adults aged 20 years and older.4 Lung cancer diagnoses account for innumerable healthcare visits
each year; however, there are no exact estimates for small cell lung carcinoma versus NSCLC. It
is estimated that around 228,000 newly diagnosed cases of lung cancer are treated each year,
accounting for about 14% of cancer diagnoses.1,5 Further, around 159,000 lung cancer deaths
occurred in the United States in 2013 alone.1 The commonality of the disease coupled with
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staggering healthcare costs and time is indicative of the fact that NSCLC treatment is a topic that
is relevant to both patients and the physician assistant practice.
The most important risk factor related to the development of NSCLC is smoking,
including both first- and second-hand smoke. Other risk factors include environmental exposures,
such as radon, asbestos, and air pollution, and a personal or family history of lung cancer.
Although lung cancer may present as an incidental finding on imaging, the most common
presenting symptoms include worsening cough, chest pain, or hemoptysis.1 Due to the fact that
NSCLC frequently presents as metastatic disease, clinicians also look for signs of distant
metastases, such as malaise, weight loss, dyspnea, and hoarseness.1
Vascular endothelial growth factor (VEGF), which is commonly associated with NSCLC,
promotes tumor growth and progression via angiogenesis. Bevacizumab is a monoclonal antiVEGF antibody that inhibits angiogenesis, thereby slowing the growth of carcinoma.
Bevacizumab has shown clinical improvement in various cancers, including NSCLC.2
Consequently, bevacizumab as adjunctive treatment has not been studied comprehensively as to
which combination of traditional chemotherapy would provide the most benefit, nor has it been
studied extensively as a monotherapy for NSCLC.
There are several therapeutic treatment options available for patients with NSCLC; yet,
results of standard treatment are often poor because most NSCLC diagnoses present as
metastatic disease, rather than localized.2 In NSCLC, surgery is the most theoretically curative
treatment for patients. Postoperative chemotherapy and/or radiation therapy may provide
additional benefit. Patients who present with advanced stage disease have shown improvement
from chemotherapy and/or epidermal growth factor receptor (EGFR) kinase inhibitors. 1 The
standard treatment options for patients with stage IIIb NSCLC include postoperative
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chemotherapy, combination chemotherapy and radiation therapy, and/or radiation therapy alone.
The first-line treatment options for patients with stage IV NSCLC are combination
chemotherapy, combination chemotherapy with bevacizumab, or EGFR tyrosine kinase
inhibitors. Other traditional treatment options for stage IV NSCLC include endobronchial laser
therapy and/or brachytherapy or external-beam radiation therapy.1 Each option mentioned plays
a role in treatment depending on the stage and histologic grade of the NSCLC. The use of
bevacizumab has been shown to be effective in the treatment of grade IIIb and IV NSCLC when
combined with specific types of adjuvant chemotherapy. This selective evidence-based medicine
(EBM) review evaluated RCTs to examine the effectiveness of bevacizumab as adjuvant
chemotherapy in the treatment of NSCLC.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not bevacizumab
(avastin) is safe and effective as adjuvant chemotherapy for adult patients with stage IIIb or IV
NSCLC.
METHODS
Specific selection criteria for the RCTs were used for this EBM review. The population
chosen was adults > 18 years old with stage IIIb or IV NSCLC. The intervention utilized in each
study was bevacizumab adjuvant chemotherapy. Comparisons were made between traditional
chemotherapy, such as paclitaxel-carboplatin, erlotinib, or cisplatin-gemcitabine, plus
bevacizumab and traditional chemotherapy plus placebo or chemotherapy alone. Outcomes
measured were based on patient oriented evidence that matters (POEMs), specifically, the overall
survival (OS) and progression-free survival (PFS). The study types included three RCTs
comparing bevacizumab adjuvant chemotherapy to traditional treatment options.
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Key words used in the searches were “non-small cell lung cancer,” “avastin,”
“bevacizumab,” and “adjuvant chemotherapy.” All articles were published in peer-reviewed
journals and in the English language. The author researched the articles via PubMed, Medline,
and OVID. Articles were selected based on their relevance to the author’s EBM question, in
addition to the inclusion of study outcomes that mattered to the patients (POEMs). Studies that
were RCTs published after 1996 and studies with patients over the age of 18 years old with stage
IIIb or IV NSCLC were included. Studies with patients under the age of 18 years old and/or with
stage I through IIIa NSCLC were excluded. Additional demographics and characteristics related
to each study are included in Table 1. The statistics used in the studies to evaluate the patient
outcomes included ABI, HR, NNT, and RBI.2,3,6
OUTCOMES MEASURED
The outcomes measured were based on OS and/or PFS. OS was defined as time from
randomization to death from any cause. PFS was defined as time from randomization to first
documented disease progression or death on study treatment, whichever occurred first. Outcomes
were evaluated using stratified Cox proportional hazard models to estimate hazard ratios,
comparing how often survival occurred with the addition of bevacizumab to how often it
occurred with traditional chemotherapy alone. Event-time distributions were estimated using the
Kaplan-Meier method.2,3,6
RESULTS
The data collected from the Sandler et al and Reck et al RCTs was in dichotomous form,
while data collected from the Herbst et al RCT was in continuous form. Herbst et al2 and Reck et
al6 compared traditional chemotherapy plus bevacizumab to traditional chemotherapy plus
placebo, while Sandler et al3 compared traditional chemotherapy plus bevacizumab to traditional
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chemotherapy alone.
Table 1 – Demographics and characteristics of included studies
Study

Type

# Pts

Age
Inclusion
(yrs)
Criteria
18+ Patients 18+
y/o
y/o who had
SCC and had
received
neoadjuvant
or adjuvant
therapy for
stage I-IIIa
disease with
ECOG
performance
score of 0 to 1

Herbst,
20112

Double- 636
blind
RCT

Reck,
20096

Double- 1043 18+
blind
y/o
RCT

Sandler, RCT
20063

878

18+
y/o

Patients 18+
y/o who had
stage IIIb or
IV NSCLC
with ECOG
performance
score of 0 to 1

Patients 18+
y/o who had
stage IIIb or
IV NSCLC
with ECOG
performance
score of 0 to 1

Exclusion Criteria
Pts with an MI
within the past 6
mo, UA, CHF,
arrhythmia, PVD,
uncontrolled HTN,
h/o of hemoptysis,
presence of a tumor
invading blood
vessels, bleeding
diathesis, another
invasive CA within
5 yrs prior to
randomization,
current use of
aspirin or NSAIDs,
previous tx with
anti-EGFR or antiVEGF agents,
surgery 28 d before
study
Pts with SCLC, h/o
hemoptysis, CNS
metastasis, h/o
thrombotic d/o,
current use of
aspirin, CVD,
uncontrolled HTN,
surgery 4 wk before
study, presence of a
tumor invading
blood vessels
Pts with
hemoptysis, CNS
metastasis, bleeding
diathesis, current
use of NSAIDs,
major surgery 28 d
before enrollment,
CVD, uncontrolled
HTN

W/D

Interventions

0

Erlotinib plus
bevacizumab

0

Cisplatin and
gemcitabine
plus
bevacizumab

0

Paclitaxel and
carboplatin
chemotherapy
plus
bevacizumab
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Herbst et al2 conducted a randomized controlled double-blind clinical trial that involved
enrolling 636 patients at 177 study sites in 12 countries from June 8, 2005 to April 16, 2008. 319
patients were randomly assigned to the traditional chemotherapy (erlotinib) plus bevacizumab
group, and 317 patients were assigned to the erlotinib plus placebo group. Median follow-up
time for patients in either group was 19 months after initial enrollment date. The investigators
reported no difference in OS between the groups, as median OS was around 9.2 to 9.3 months in
both placebo and bevacizumab groups. Hazard ratios were estimated through use of an
unstratified Cox model, which produced a HR of 0.97 with a 95% CI (0.80-1.18) and p-value of
0.7583 (Table 2).2 PFS appeared to differ significantly among the bevacizumab and placebo
groups in this study. Herbst et al2 reported results as 3.4 months in the bevacizumab group
compared to 1.7 months in the control group. However, results were not reported as statistically
significant due to the fact that fixed-sequence testing was used in order to control the overall type
I error rate.2
Table 2 – Efficacy of erlotinib plus bevacizumab in comparison to erlotinib plus placebo
measured via overall survival hazard ratio2
Bevacizumab Placebo
Hazard Ratio P-value
95% CI
Median OS,
Median OS,
months (IQR) months (IQR)
Overall
9.2, (3.8 –
9.3, (4.1-21.6) 0.97
0.7583
(0.80-1.18)
Survival (OS) 20.2)
Reck et al6 conducted a RCT that involved randomly assigning 1,043 patients at 150
study sites in 20 countries between February 2005 and August 2006 to three different groups.
347 patients were randomly assigned to the traditional chemotherapy (cisplatin-gemcitabine)
plus placebo group, 345 patients were assigned to the cisplatin-gemcitabine plus low-dose
bevacizumab group, and 351 patients were assigned to the cisplatin-gemcitabine plus high-dose
bevacizumab group. Traditional chemotherapy was administered every three weeks for up to six
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cycles, and bevacizumab or placebo was administered every three weeks until either the disease
progressed or adverse events were intolerable. The investigators reported insufficient follow-up
time for OS analysis.6 Conversely, a considerable difference in PFS was noted in both of the
low- and high-dose bevacizumab groups compared to the control. Median PFS was around 6.7
months in the group assigned to low-dose bevacizumab and 6.5 months in the group assigned to
high-dose bevacizumab, compared to 6.1 months in the chemotherapy plus placebo group.
Hazard ratios were determined via Kaplan-Meier estimates, which produced a low-dose
bevacizumab HR of 0.75 with a 95% CI (0.62-0.91), and p-value of 0.003. The high-dose
bevacizumab HR was 0.82 with a 95% CI (0.68-0.98), and p-value 0.03 (Table 3). 6
Table 3 – Efficacy of cisplatin and gemcitabine plus either low- or high-dose bevacizumab in
comparison to cisplatin and gemcitabine plus placebo measured via progression-free survival
hazard ratio6
Low-dose
High-dose
Placebo Hazard Ratio P-Value
95% CI
Bevacizumab Bevacizumab PFS
Median PFS Median PFS
Low- High- Low- High- Low- HighDose Dose Dose Dose Dose Dose
Progression- 6.7 months
6.5 months
6.1
0.75 0.82 0.003 0.03 (0.62- (0.68Free
months
0.91) 0.98)
Survival
(PFS)
Sandler et al3 conducted a randomized controlled double-blind clinical trial that involved
enrolling 878 patients from July 2001 to April 2004. 434 patients were randomly assigned to the
traditional chemotherapy (paclitaxel-carboplatin) plus bevacizumab group, and 444 patients were
assigned to the paclitaxel-carboplatin alone group. The traditional chemotherapy was
administered every three weeks for six cycles, and bevacizumab was administered every three
weeks until either the disease progressed or adverse events were intolerable. The investigators
reported a considerable difference in OS between the groups. Median OS was around 12.3
months in the group assigned to traditional chemotherapy plus bevacizumab, compared to 10.3
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months in the chemotherapy-alone group. Hazard ratios were determined via Kaplan-Meier
estimates, which produced a HR of 0.79 with a 95% CI (0.67-0.92) and p-value of 0.003.3 PFS
also appeared to be statistically significant when comparing the bevacizumab and chemotherapyalone groups in this study. Sandler et al3 reported results as 6.2 months in the bevacizumab group
compared to 4.5 months in the control group. Hazard ratios were estimated by use of an
unstratified Cox model, which produced a HR of 0.66 with a 95% CI (0.57-0.77) and p-value <
0.001 (Table 4).3
Table 4 – Efficacy of paclitaxel and carboplatin plus bevacizumab in comparison to paclitaxel
and carboplatin alone measured via overall survival hazard ratio3
Bevacizumab Chemotherapy Hazard Ratio P-value
95% CI
1-year OS, 2- alone 1-year
year OS
OS, 2-year OS
Overall
51%, 23%
44%, 15%
0.79
0.003
(0.67-0.92)
Survival (OS)
Table 5 shows relative benefit increase (RBI) for overall survival, which was statistically
significant in both Herbst et al2 and Sandler et al3 studies, with the addition of bevacizumab to
traditional chemotherapy. For the Herbst et al2 study, the RBI was calculated to be 32% and
absolute benefit increase was 11%. Numbers needed to treat (NNT) was calculated as 9, meaning
that nine patients need to be treated with bevacizumab compared to traditional chemotherapy
alone in order to have one person have improved overall survival. For the Sandler et al3 study,
the RBI was calculated to be 16% and absolute benefit increase was 7%. NNT was calculated as
14, meaning that fourteen patients need to be treated with bevacizumab compared to traditional
chemotherapy alone in order to have one person benefit from this type of treatment.
Table 5 – Benefit of bevacizumab on overall survival
Erlotinib plus bevacizumab in comparison to erlotinib plus
placebo (Herbst et al)2
Paclitaxel and carboplatin plus bevacizumab in comparison to
paclitaxel and carboplatin alone (Sandler et al)6

CER EER RBI ABI NNT
34% 45% 32% 11% 9
44%

51% 16% 7%

14
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Adverse events (AE) were also measured in each of the RCTs. Herbst et al2 reported 42%
of the bevacizumab group compared to 36% of the control group with a serious AE > grade 3.
Reck et al6 reported similar findings between the bevacizumab group and the control group with
regards to AEs. The investigators of this study reported 81% of the high-dose bevacizumab and
76% of the low-dose bevacizumab compared to 75% of the control group with a serious AE >
grade 3.6 Finally, Sandler et al3 reported several significant AEs that occurred more often in the
bevacizumab group, compared to the control group (Table 6).
Table 6 – Adverse events reported with administration of bevacizumab3
Adverse Event
Bevacizumab Group
Control Group
# of patients (%)
# of patients (%)
Neutropenia
109 (25.5)
74 (16.8)
Hypertension
30 (7)
3 (0.7)
Proteinuria
13 (3.1)
0 (0)
Headache
13 (3.0)
2 (0.5)
Bleeding event
19 (4.4)
3 (0.7)

P-Value
0.002
<0.001
<0.001
0.003
<0.001

Table 7 shows relative risk increase (RRI) for adverse events (AE), which was
statistically significant in the Sandler et al3 study. Numbers needed to harm (NNH) was
calculated for each significant AE. The most significant result, headache, had an NNH that was
calculated as 40, meaning that forty patients need to be treated with bevacizumab compared to
traditional chemotherapy alone in order to have one person experience AE of headache.
Table 7 – Risk of bevacizumab on adverse events
CER
EER
Neutropenia
16.8%
25.5%
Hypertension
0.7%
7%
Proteinuria
0%
3.1%
Headache
0.5%
3%
Bleeding event
0.7%
4.4%

RRI
52%
900%
N/A
500%
529%

ARI
8.7%
6.3%
3.1%
2.5%
3.7%

NNH
11
16
32
40
27

DISCUSSION
This systematic review investigated three RCTs for the safety and efficacy of
bevacizumab as adjuvant chemotherapy for adult patients, 18 years of age and older, with stage
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IIIb or IV NSCLC. The study by Herbst et al2 failed to find a significant difference in OS or PFS
between subjects using adjuvant bevacizumab and those using traditional chemotherapy. While
the Reck et al6 study was unable to assess OS; the investigators did find that PFS was
significantly improved with the addition of bevacizumab to traditional chemotherapy. The study
by Sandler et al3 established that the addition of bevacizumab to traditional chemotherapy has
statistically significant survival benefits in patients with NSCLC.
Bevacizumab is FDA approved to treat NSCLC, metastatic colorectal cancer, metastatic
HER2 negative breast cancer, and metastatic renal cell carcinoma.7 It is also approved for
second-line treatment of glioblastoma. The drug has a black box warning for gastrointestinal
perforations, wound healing complications, and hemorrhage.7 Most importantly, fatal pulmonary
hemorrhage has been reported in patients with NSCLC treated with chemotherapy plus
bevacizumab.7 This significant AE was demonstrated in a small percentage of patients in each of
the RCTs, which is important when considering future studies.2,3,6
Limitations were present in each RCT, which affect their validity regarding the question
of concern. Herbst et al2 reported that crossover effects from using a potentially active
chemotherapeutic agent, bevacizumab, were not monitored throughout the study. Furthermore,
Herbst et al2 utilized subsequent lines of therapy during follow-up more often in the control
group than in the bevacizumab group, which most likely confounded the comparison of OS
between the two groups. In both the Reck et al6 and Sandler et al3 studies, confounding variables
such as favorable prognostic features of the patient population may have influenced the favorable
outcome of increased OS and PFS. For example, Reck et al6 revealed that the overall patient
population was younger with a higher incidence of less severe stage IIIb NSCLC as compared to
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similar studies regarding bevacizumab and NSCLC. Finally, each of the three RCTs
acknowledged financial support by Genentech and Roche, the marketers of bevacizumab.2,3,6
CONCLUSION
From the research performed and results obtained, the evidence is inconclusive and
conflicting to support the use of bevacizumab as adjuvant chemotherapy for stage IIIb or IV
NSCLC. Herbst et al2 found that the addition of bevacizumab to traditional chemotherapy
(erlotinib) does not improve OS or PFS in NSCLC patients. However, Reck et al6 found that the
addition of bevacizumab to traditional chemotherapy (cisplatin-gemcitabine) significantly
improves only PFS rates. Finally, Sandler et al2 found that the addition of bevacizumab to
traditional chemotherapy (paclitaxel-carboplatin) has statistically significant OS and PFS
benefits.
With inconsistencies and differing results among the three RCTs, further research would
be helpful to confirm or negate the question of whether bevacizumab is actually beneficial as
adjuvant chemotherapy. More importantly, stricter guidelines should be applied to future
research regarding patient population characteristics, as well as the addition of bevacizumab to
one specific traditional chemotherapy. In addition to researching the efficacy and safety of
bevacizumab as adjuvant chemotherapy, it would be advantageous to study the efficacy and
safety of bevacizumab as monotherapy. Comparisons can be made between the use of the drug as
an adjunctive treatment versus the use of the drug as a single drug treatment for NSCLC.
Continued research on bevacizumab for NSCLC will be beneficial to patients who are refractory
to initial treatments of the disease. Further research is warranted to obtain more conclusive data.
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